? 澳洲幸运8玩法

Dr. C.L. CHEUNG 張正龍

Assistant Professor

  • BSc, PhD
Biography
Dr Ching-Lung Cheung obtained his PhD in genetic epidemiology of osteoporosis at the University of Hong Kong (HKU). He received post-doctoral training in the Institue For Aging Research, Hebrew SeniorLife, Harvard Medical School under the supervisior of Prof. Doug Kiel and Dr. David Karasik; Genome Institute of Singapore, A*STAR, Singapore, and HKU. In 2013, Dr. Cheung took up his post as Research Assistant Professor at HKU. In 2013, he was appointed as honorary research fellow in the Institute of Translational Medicine, The University of Liverpool, UK, and worked with Prof. Sir Munir Pirmohamed. He is the principal investigator of a number of research projects funded by RGC and HMRF.
Dr. Cheung and his research associates

Dr. Cheung and his research associates


Memberships & Editorships
Memberships:
  • Committee Member of American Society of Bone and Mineral Research (ASBMR), United States
  • Honorary treasurer of Osteoporosis Society of Hong Kong, Hong Kong
  • Honorary treasurer of Institute of Cardiovascular Science and Medicine, Hong Kong
  • Committee Member of Hong Kong Pharmacology Society, Hong Kong
Honours and Awards
  • Early Career Award, Research Grants Council, University Grants Committee, Hong Kong, 2016
  • Research Output Prize: Faculty of Medicine, the University of Hong Kong, 2013
  • New Investigator Award: 2011 Joint conference of European Calcified Tissue Society and International Bone and Mineral Society, 2011, and
  • Poster and Oral Presentation Awards from:
    • Plenary oral presentation award, the 4th Seoul International Congress of Endocrinology and Metabolism, Seoul, Korea (2016)
    • The 21st Medical Research Conference, the University of Hong Kong (2016);
    • 9th Metabolic Syndrome, Type 2 Diabetes and Atherosclerosis Congress, Kyoto, Japan (2014);
    • APSAVD-EMW Young Investigator Oral Award – Winner: 9th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases and 16th Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Hong Kong (2014);
    • 19th Medical Research Conference, the University of Hong Kong (2014);
    • 16th Annual Scientific Meeting of Institute of Cardiovascular Science and Medicine (2012);
    • 2010 Annual Meeting of the Hong Kong Society of Endocrinology, Metabolism and Reproduction (2010)

Research Interests

Precision medicine is an emerging form of disease prediction, diagnosis, and prevention that uses genetics, biomarkers, and other personalized information to deliver the right treatment, to the right person, at the right time. As the underlying cause of disease could be different among patients, the use of Precision Medicine should both improve patient outcomes and deliver benefits to the health service, based on patient's individualized makeup. In addition, the use of information from research of precision medicine can also lead to new drug and biomarker discovery.

Currently, there are several strategic areas under the supervision of Dr. Cheung, including osteoporosis and sarcopenia, other endocrine disorders, and cancer.

Osteoporosis

Dr. Cheung is the prinicipal investigator of the Hong Kong Osteoporosis Study, a cohort study of osteoporosis that established in 1995 by Prof. Annie Kung. Together with the availability of other related omics (genome-wide genotyping and metabolomics with > serum 1000 metabolites) and big data, we are currently working in the following areas:   

  1. Multiomics of osteoporosis;
  2. Development of fracture prediction algorithm;
  3. Development of novel supplement for improving bone and muscle health;
  4. Development of novel biomarker of osteoporosis and sarcopenia; and
  5. Pharmacoepidemiology of bone related diseases.

Other endocrine disorders

We have been working in other endocrine disorders, such as thyroid diseases and diabetes.

Cancer

With the collaboration with several clinical oncologists, we have started developing risk prediction algorithm using big data coupled with advance machine learning approaches. We are particularly interested in cancers that are related to adverse bone outcomes, such as breast cancer, prostate cancer, and bone metastasis.

Development of precision medicine using integrative approach

Development of precision medicine using integrative approach



Publications
Publications Highlights
Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Chan EW, Kung AW, Wong IC, Cheung CL*(*Corresponding author) (2018) Association of Alendronate and Risk of Cardiovascular Events in Patients with Hip Fracture. Journal of Bone and Mineral Research (Accepted) 
(Endocrinology & Metabolism: 2016 ISI impact factor: 6.3; Percentile: 90.2)  Moayyeri A*, Cheung CL* (*Co-first author), Tan KCB, Morris JA, Cerani A, Mohney RP, Richard JB, Hammond C, Spector TD, Menni C (2018) Metabolomic pathways to osteoporosis in middle-aged women: A genome-metabolome-wide Mendelian randomization study. Journal of Bone and Mineral Research (Accepted) 
(Endocrinology & Metabolism: 2016 ISI impact factor: 6.3; Percentile: 90.2) Cheung CL* (*Corresponding author), Sing CW, Tang CSM, Cheng VKF, Pirmohamed M, Choi CH, Hung CS, Lau E, Lee KF, Mak MW, Leung J, Wong TW, Ho AYY, Chan KW, Hung V, Tam V, Siu SC, Sham PC, Cheung BMY, Wong ICK, Tan KCB, Kung AWC. (2016) HLA-B*38:02:01 Predicts Carbimazole/Methimazole-Induced Agranulocytosis. Clinical Pharmacology and Therapeutics;99(5):555-61 
(Pharmacology & Pharmacy: 2016 ISI impact factor: 7.3; Percentile: 95.5) Cheung CL* (*Corresponding author), Lau KS, Ho AY, Lee KK, Tiu SC, Lau EY, Leung J, Tsang MW, Chan KW, Yeung CY, Woo YC, Cheung ENY, Hung VHF, Pang HK, Hung CS, Sham PC*, Kung AWC*. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3. Nature Genetics;44:1026-1029 
(Genetics & Heredity: 2012 ISI impact factor: 35.2; Percentile: 99.1)

Selected Publications

10 selected publications in the past 5 years:

  • Li GHY, Cheung CL* (*Corresponding author), Au PCM, Tan KCB, Wong ICK, Sham PC. (2019) Positive effects of low LDL-C and statins on bone mineral density: an integrated epidemiological observation analysis and Mendelian Randomization study. Int J Epidemiol (2018 ISI 5-year impact factor: 9.8)
  • Lam MT, Sing CW, Li GHY, Kung AWC, Tan KCB, Cheung CL* (*Corresponding author) (2019) Development and Validation of a Risk Score to Predict the First Hip Fracture in the Oldest Old: A Retrospective Cohort Study. Journals of Gerontology series A-Biological Sciences and Medical Sciences (Accepted) (2018 ISI 5-year impact factor: 5.8)
  • Leung RYH, Cheung BMY, Tan KCB, Kung AWC, Cheung CL* (*Corresponding author) (2019) Serum metabolomic profiling and its association with 25-hydroxyvitamin D. Clin Nutr (2018 ISI 5-year impact factor: 6.0)
  • Cheung CL* (*Corresponding author), Tan KCB, Au PCM, Li GHY, Cheung BMY. (2019) Evaluation of GDF15 as a Therapeutic Target of Cardiometabolic Diseases in Human: A Mendelian Randomization Study. EBioMedicine;41:85-90 (ISI 5-year impact factor: 6.5)
  • Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Chan EW, Kung AW, Wong IC, Cheung CL* (*Corresponding author) (2018) Association of Alendronate and Risk of Cardiovascular Events in Patients with Hip Fracture. J Bone Miner Res:33(8):1422-34 (2018 ISI 5-year impact factor: 6.2)
  • Cheung CL* (*Corresponding author), Tan KC, Kung AW. Cohort Profile: The Hong Kong Osteoporosis Study and the follow-up study. (2018) Int J Epidemiol;47(2):397-398f (2018 5-year impact factor: 9.8)
  • Moayyeri A*, Cheung CL* (*Co-first author), Tan KCB, Morris JA, Cerani A, Mohney RP, Richard JB, Hammond C, Spector TD, Menni C (2018) Metabolomic pathways to osteoporosis in middle-aged women: A genome-metabolome-wide Mendelian randomization study. J Bone Miner Res;33:643-650 (2018 5-year ISI impact factor: 6.2)
  • Lau WCY, Chan EW, Cheung CL, Sing CW, Man KKC, Lip GYH, Siu CW, Lam JKY, Lee ACH, Wong IC. (2017) Association between Dabigatran versus Warfarin and Risk of Osteoporotic Fractures among Patients with Nonvalvular Atrial Fibrillation. JAMA; 317(11):1151-1158 (2017 5-year ISI impact factor: 42.5).
  • Cheung CL* (*Corresponding author), Sing CW, Tang CSM, Cheng VKF, Pirmohamed M, Choi CH, Hung CS, Lau E, Lee KF, Mak MW, Leung J, Wong TW, Ho AYY, Chan KW, Hung V, Tam V, Siu SC, Sham PC, Cheung BMY, Wong ICK, Tan KCB, Kung AWC. (2016) HLA-B*38:02:01 Predicts Carbimazole/Methimazole-Induced Agranulocytosis. Clinical Pharmacology and Therapeutics;99(5):555-61 (2016 5-year ISI impact factor: 6.9)
  • Dalgaard K, Landgraf K, Heyne S, Lempradl A, Longinotto J, Gossens K, Ruf M, Orthofer M, Strogantsev R, Selvaraj M, Lu TTH, Casas E, Teperino R, Surani MA, Zvetkova I, Rimmington D, Tung YCL, Lam B, Larder R, Yeo GSH, O’Rahilly S, Whitelaw E, Penninger JM, Jenuwein T, Cheung CL, Ferguson-Smith AC, Coll AP, Körner A, Pospisilik JA (2016) Loss of Trim28 triggers bi-stable epigenetic obesity: Evidence for polyphenism in mouse and man. Cell; 164(3):353–364 (2016 5-year ISI impact factor: 34.1)

10 selected publications beyond past 5 years:

  • Cheung CL* (*Corresponding author), Lam KSL, Wong ICK, Cheung BMY. (2014) Non-invasive Score Identifies Ultrasound-diagnosed Non-Alcoholic Fatty Liver Disease and Predicts Mortality in United States. BMC Medicine; 10;12:154 (2014 ISI impact factor: 7.3)
  • Cheung CL* (*Corresponding author), Lau KS, Sham PC, Tan KC, Kung AW. (2013) GREM2 is Significantly Associated with Bone Mineral Density in Southern Chinese. J Clin Endo Metab;98:E1557-61 (2013 ISI impact factor: 6.3)
  • Cheung CL, Tan KCB, Lam KSL, Cheung BMY. (2013) The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: A structural equation modeling approach. J Clin Endo Metab;98(9):3856-63 (2013 ISI impact factor: 6.3)
  • Cheung CL* (*Corresponding author), Lau KS, Ho AY, Lee KK, Tiu SC, Lau EY, Leung J, Tsang MW, Chan KW, Yeung CY, Woo YC, Cheung ENY, Hung VHF, Pang HK, Hung CS, Sham PC*, Kung AWC*. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3. Nat Genet;44:1026-1029 2012 ISI impact factor: 35.2)
  • Li GH^, Cheung CL^ (*Corresponding author), Xiao SM, Lau KS, Gao Y, Bow CH, Huang QY, Sham PC, Kung AW (2011) Identification of QTL genes for BMD variation using both linkage and gene-based association approaches. (^co-first author) Hum Genet;130(4):539-46 (2011 ISI impact factor: 5.1)
  • Cheung CL, Livshits G, Zhou Y, Meigs JB, McAteer JB, Florez JC, Cupples LA, Demissie S, Kiel DP, Karasik D. (2010) Hip Geometry Variation Is Associated with Bone Mineralization Pathway Gene Variants: the Framingham Study. J Bone Miner Res;25:1564-1571 (2010 ISI impact factor: 7.1)
  • Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study, Lancet;376;180-8 (2010 ISI impact factor: 33.6)
  • Cheung CL, Sham PC, Chan V, Paterson AD, Luk KDK, Kung AWC. (2008) Identification of LTBP2 on Chromosome 14q as a Novel Candidate Gene for BMD Variation and Fracture Risk Association. J Clin Endo Metab; 93:4448-55. (2008 ISI impact factor: 6.3)
  • Cheung CL, Chan BYY, Chan V, Ikegawa S, Kou I, Ngai H, Smith DK, Huang QY, Mori S, Sham PC, Kung AWC. (2009) Pre-B-Cell Leukemia Homeobox 1 (PBX1) Shows Genetic and Functional Association with Bone Mineral Density Variation. Hum Mol Genet;18:679-87 (2009 ISI impact factor: 7.4)
  • Tang PLF*, Cheung CL*,(*co-first author) Sham PC, McClurg P, Lee B, Chan WY, Smith DK, Tanner JA, Su AI, Cheah KSE, Kung AWC, Song YQ. (2009) Genome-wide haplotype association mapping in mice identifies a genetic variant in CER1 associated with bone mineral density and fracture in southern Chinese women. J Bone Miner Res;24:1013-21 (2009 ISI impact factor: 6.0)

Funding

From 2014 to 2019: 9 grants as PI from 4 funding bodies, with the total funding over HKD$12M

For example

  • RGC (17104314): “Genetics and genomics of anti-thyroid drug induced agranulocytosis” 2014/2015 (HKD$905,558 for three years, PI)
  • RGC/ECS (27100416): “Metabolomic Study of Osteoporosis in Southern Chinese” 2016/2017 (HKD$ 1,455,193 for four years, PI)
  • NSFC/RGC joint grant (N_HKU729/16): “Identification of susceptibility genes involved in the pathogenesis and prediction of thyrotoxic periodic paralysis” 2016/2017 (HKD$956,480 for four years, PI)
  • S.K. Yee Medical foundation grant (2161218): “Genetic screening service of HLA-B*38:02 in people prescribing antithyroid drug” 2016/2017 (HKD$899,708 for 2 years, PI)
  • HMRF (05162796): “AKAP11 as a positive regulator of osteogenesis” 2017/2018 (HKD$1,198,862 for two years, PI)
  • Beat Drug Fund (grant number NA): “A Comprehensive Program for Evaluation of Musculoskeletal Health and Pharmacist Medication Review” 2017/2018 (HKD$2,828,995.4 for three years, PI)

Other Information

 

Seeking MPhil/PhD candidates:

The Department of Pharmacology and Pharmacy is inviting graduate students who are interested in conducting translational research in the area of "Pharmacogenomics and Precision Medicine" to join the Department. We are interested in the following research goals:

  1. To develop precision medicine for osteoporosis and related diseases and traits by combining lifestyle, clinical risk factors, biomarkers, and genetic/genomic risk factors. We are devoted to develop algorithms to predict disease risk, accurate diagnose, and optimize treatment for patients based on their personal, clinical, and genetic profiles.
  2. To avoid adverse drug reaction of commonly used medication by identification of the associated genetic marker(s). Screening of patients prior medication will help enhancing safe medication.

For further information about the project and suitability, please email Dr. Ching-Lung Cheung (email: [email protected]).

Current Group Members (2019)
  • Dr. Chor-Wing Sing (Postdoctoral fellow)
  • Dr. Gloria Li (Postdoctoral fellow)
  • Dr. Raymond Leung (Technician)
  • Ms. Donna Ng (Research pharmacist)
  • Miss. Constance Mak (Research nurse)
  • Mr. Vincent Cheng (PhD student)
  • Ms. Pallas Chau (MPhil student)
  • Ms. Jessica Wong (Part-time MPhil student/ pharmacist)
  • Mr. Warrington Hsu (Part-time MPhil student/ statistician)
  • Mr. Philip Au (Research assistant)
  • Mr. Sam Lam (Research assistant)
  • Mr. Ricky Wong (Research assistant)
Regular Student Consultation Hours
Every Friday at 5:00pm - 6:00pm
Office

L2-52, Lab Block, LKS Faculty of Medicine, 21 Sassoon Road, Pokfulam, Hong Kong


澳洲幸运8是官方的吗